Login to Your Account

Corcept Plummets On Failed Corlux Phase III Trial For PMD

By Karen Pihl-Carey

Monday, August 28, 2006
Corcept Therapeutics Inc.'s antipsychotic drug, Corlux, failed in its first Phase III trial, devastating the company's stock, which lost more than half of its value. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription